Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Intravenous dihydroergotamine for inpatient management of refractory primary headaches.

Nagy AJ, Gandhi S, Bhola R, Goadsby PJ.

Neurology. 2011 Nov 15;77(20):1827-32. doi: 10.1212/WNL.0b013e3182377dbb. Epub 2011 Nov 2.

PMID:
22049203
2.
3.

Dosing and administration of ergotamine tartrate and dihydroergotamine.

Mathew NT.

Headache. 1997;37 Suppl 1:S26-32. Review.

PMID:
9009471
4.

Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache.

Carleton SC, Shesser RF, Pietrzak MP, Chudnofsky CR, Starkman S, Morris DL, Johnson G, Rhee KJ, Barton CW, Chelly JE, Rosenberg J, Van Valen MK.

Ann Emerg Med. 1998 Aug;32(2):129-38.

PMID:
9701293
5.

[Transformed migraine--chronic daily headache].

Bøe MG, Monstad P.

Tidsskr Nor Laegeforen. 1999 Nov 30;119(29):4311-3. Norwegian.

PMID:
10667127
6.

A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine.

Winner P, Ricalde O, Le Force B, Saper J, Margul B.

Arch Neurol. 1996 Feb;53(2):180-4.

PMID:
8639069
7.

Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache.

Swidan SZ, Lake AE 3rd, Saper JR.

Curr Pain Headache Rep. 2005 Feb;9(1):65-70.

PMID:
15625028
8.

Outpatient home-based continuous intravenous dihydroergotamine therapy for intractable migraine.

Charles JA, von Dohln P.

Headache. 2010 May;50(5):852-60. doi: 10.1111/j.1526-4610.2010.01622.x. Epub 2010 Jan 28.

PMID:
20132337
9.

Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial.

Silberstein SD, Young WB, Hopkins MM, Gebeline-Myers C, Bradley KC.

Headache. 2007 Jun;47(6):878-85.

PMID:
17578539
10.

Effectiveness of subcutaneous dihydroergotamine by home injection for migraine.

Becker WJ, Riess CM, Hoag J.

Headache. 1996 Mar;36(3):144-8.

PMID:
8984085
11.
12.

Outpatient intravenous dihydroergotamine for refractory cluster headache.

Magnoux E, Zlotnik G.

Headache. 2004 Mar;44(3):249-55.

PMID:
15012663
13.

The treatment of cluster headache with repetitive intravenous dihydroergotamine.

Mather PJ, Silberstein SD, Schulman EA, Hopkins MM.

Headache. 1991 Sep;31(8):525-32.

PMID:
1960057
14.

[Calcium carbasalate-metoclopramide combination versus dihydroergotamine in the treatment of migraine attacks].

Pradalier A, Guérard des Lauriers A, Scheck F, Peraudeau P, Lacoste JP, Cajfinger F.

Pathol Biol (Paris). 1995 Nov;43(9):806-13. French.

PMID:
8746103
15.

Chronic daily headache: long-term prognosis following inpatient treatment with repetitive IV DHE.

Silberstein SD, Silberstein JR.

Headache. 1992 Oct;32(9):439-45.

PMID:
1446987
16.

Outpatient continuous intravenous dihydroergotamine for refractory headache.

Charles JA.

Headache. 2005 Apr;45(4):394-5. No abstract available.

PMID:
15836585
17.

A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.

Aurora SK, Rozen TD, Kori SH, Shrewsbury SB.

Headache. 2009 Jun;49(6):826-37. doi: 10.1111/j.1526-4610.2009.01453.x.

PMID:
19545249
18.
19.

Aprepitant for the management of nausea with inpatient IV dihydroergotamine.

Chou DE, Tso AR, Goadsby PJ.

Neurology. 2016 Oct 11;87(15):1613-1616. Epub 2016 Sep 14.

20.

Repetitive intravenous DHE in the treatment of refractory headache.

Silberstein SD, Schulman EA, Hopkins MM.

Headache. 1990 May;30(6):334-9.

PMID:
2370132

Supplemental Content

Support Center